Skip to main content

Advertisement

SpringerLink
Log in

Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Although platinum-based two-drug combinations represent the elective therapeutic approach for advanced/metastatic NSCLC, there is still interest in exploring the efficacy and tolerability of platinum-free combinations including third generation agents in selected NSCLC population. Based on the satisfying activity of gemcitabine (G), ifosfamide (I) and paclitaxel (T) as single agents in NSCLC, we have designed a phase II study to explore an alternative approach to platinum-containing regimens using a combination of these three drugs. To investigate the activity/toxicity of T 175 mg/m2 on day 1, I 3 g/m2 on day 1 (with Mesna uroprotection) and G 1,000 mg/m2 on day 1–8, every 3 weeks in the treatment of advanced/metastatic NSCLC, 46 patients (38 male, 8 female) with NSCLC were enrolled: mean age 58 (range 33–70); Stage IIIB/IV = 15/31; ECOG PS 0-1/2 = 31/15; Histology: adenocarcinoma = 20, squamous = 14, large cell = 3, NSCLC = 8, adenosquamous = 1. A total of 221 cycles have been administered (median number 4.8 for patients). In intent-to-treat analysis, partial response was achieved in 17 patients (36.95%), stable disease and progressive disease was detected in 16 (34.78%) and 10 (21.73%) patients, respectively. Time to progression was 30.9 weeks; median survival time was 42.7 weeks; the survival rates at 12 and 18 months were 34.79 and 15.21%, respectively. No toxic deaths occurred. No patients experienced grade 4 neutropenia and thrombocytopenia. Neutropenia grade 3 occurred in 10 patients (21.7%); Anemia grade 3 in 1 (2.1%); Thrombocytopenia grade 2 in two patients (4.3%) and grade 3 in one (2.1%). Peripheral neuropathy grade 1 occurred in ten (21.7%) and grade 2 in two patients (4.3%). Additional non-haematological toxicities were mild nausea, emesis and fatigue. GIT is well tolerated and active regimen in both advanced and metastatic NSCLC. These data suggest future investigations for GIT schedule as a possible alternative to platinum-based regimens in selected advanced/metastatic NSCLC patients where survival, tolerability and quality of life are the primary goals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Belani CP, Fossella F (2005) Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104(12):2766–2774

    Article  PubMed  CAS  Google Scholar 

  2. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern cooperative oncology group trial. J Clin Oncol 18:623–631

    PubMed  CAS  Google Scholar 

  3. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367

    PubMed  CAS  Google Scholar 

  4. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18:122–130

    PubMed  CAS  Google Scholar 

  5. Non-small cell lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909

    Google Scholar 

  6. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087–1100

    PubMed  CAS  Google Scholar 

  7. Pujol JL, Quantin X, Choma D, Jacot W, Khial F (2002) Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer. Lung Cancer 38(Suppl 3):S57–S60 Review

    Article  PubMed  Google Scholar 

  8. Recchia F, Saggio G, Cesta A, Candeloro G, Rea S (2005) Paclitaxel plus gemcitabine in advanced non-small cell lung cancer patients with low performance status. Anticancer Res 25(1B):409–414

    PubMed  CAS  Google Scholar 

  9. Ichinose Y, Seto T, Semba H, Itoh K, Inoue Y, Tanaka F, Araki J, Tamanoi M, Yamamoto H, Iwamoto N (2005) UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 93(7):770–773

    Article  PubMed  CAS  Google Scholar 

  10. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and nonplatinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial. Lancet 357:1478–1484

    Article  PubMed  CAS  Google Scholar 

  11. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D (2005) Vinorelbine plus cisplatin vs docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945

    Article  PubMed  CAS  Google Scholar 

  12. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21(16):3009–3010

    Article  Google Scholar 

  13. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M for the Hellenic Cooperative Oncology Group (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578–3585

    Article  PubMed  CAS  Google Scholar 

  14. Smit E, van Meerbeeck J, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909–3917

    Article  PubMed  CAS  Google Scholar 

  15. Baldini E, Ardizzoni A, Prochilo T, Cafferata MA, Boni L, Tibaldi C, Neumaier C, Conte PF, Rosso R (2001) Italian lung cancer task force. Gemcitabine, ifosfamide and navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). Br J Cancer 85(10):1452–1455

    Article  PubMed  CAS  Google Scholar 

  16. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology: treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353

    Article  PubMed  Google Scholar 

  17. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non–platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936

    Article  PubMed  CAS  Google Scholar 

  18. Le Chevalier T (1996) Single-agent activity of gemcitabine in advanced non-small cell lung cancer. Semin Oncol 23(5 Suppl 10):36–42

    PubMed  CAS  Google Scholar 

  19. Kelly K (1999) The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer. Ann Oncol 10(Suppl 5):S53–S56

    Article  PubMed  Google Scholar 

  20. Eberhardt W, Niederle N (1992) Ifosfamide in non-small cell lung cancer: a review. Semin Oncol 19(Suppl 1):40–48

    PubMed  CAS  Google Scholar 

  21. Hainsworth JD, Thompson DS, Greco FA (1995) Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13(7):1609–1614

    PubMed  CAS  Google Scholar 

  22. Balducci L, Hardy CL, Lyman GH (2000) Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control 7(6):539–547

    PubMed  CAS  Google Scholar 

  23. Balducci L (2000) Geriatric oncology: challenges for the new century. Eur J Cancer 36(14):1741–1754

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical-Surgical Oncology and Thoracic Diseases, AORN Monaldi, Via L Bianchi, 80131, Naples, Italy

    F. V. Piantedosi, F. Caputo, G. Mazzarella, M. Gilli, A. Pontillo, D. D’Agostino & S. A. Marsico

  2. Department of Health Sciences, Faculty of Medicine and Surgery, University of Molise, Via F De Sanctis, 86100, Campobasso, Italy

    S. Campbell & A. Bianco

Authors
  1. F. V. Piantedosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Caputo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Mazzarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Gilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Pontillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. D’Agostino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. A. Marsico
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Bianco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Bianco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piantedosi, F.V., Caputo, F., Mazzarella, G. et al. Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol 61, 803–807 (2008). https://doi.org/10.1007/s00280-007-0537-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0537-1

Keywords

Search

Navigation